AZ Licensing Deal Boosts Mereo Orphan Disease Model
UK group Mereo BioPharma is paying a very reasonable $5m to get its hands on AstraZeneca’s Phase II compound for the rare genetic disorder AATD.
UK group Mereo BioPharma is paying a very reasonable $5m to get its hands on AstraZeneca’s Phase II compound for the rare genetic disorder AATD.